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Sex-Speciﬁc Differences in Survival and Heart Failure
Hospitalization After Cardiac Resynchronization Therapy
With or Without Deﬁbrillation
Francisco Leyva, MD; Tian Qiu, PhD; Abbasin Zegard, MB, ChB; David McNulty, PhD; Felicity Evison, PhD; Daniel Ray, PhD;
Maurizio Gasparini, MD
Background-—Women are underrepresented in cardiac resynchronization therapy (CRT) trials. Some studies suggest that women
fare better than men after CRT. We sought to explore clinical outcomes in women and men undergoing CRT-deﬁbrillation or CRT-
pacing in real-world clinical practice.
Methods and Results-—A national database (Hospital Episode Statistics for England) was used to quantify clinical outcomes in
43 730 patients (women: 10 890 [24.9%]; men: 32 840 [75.1%]) undergoing CRT over 7.6 years, (median follow-up 2.2 years,
interquartile range, 1–4 years). In analysis of the total population, the primary end point of total mortality (adjusted hazard ratio
[aHR], 0.73; 95% CI, 0.69–0.76) and the secondary end point of total mortality or heart failure hospitalization (aHR, 0.79, 95% CI
0.75–0.82) were lower in women, independent of known confounders. Total mortality (aHR, 0.73; 95% CI, 0.70–0.76) and total
mortality or heart failure hospitalization (aHR, 0.79; 95% CI, 0.75–0.82) were lower for CRT-deﬁbrillation than for CRT-pacing. In
analyses of patients with (aHR, 0.89; 95% CI, 0.80–0.98) or without (aHR, 0.70; 95% CI, 0.66–0.73) a myocardial infarction, women
had a lower total mortality. In sex-speciﬁc analyses, total mortality was lower after CRT-deﬁbrillation in women (aHR, 0.83;
P=0.013) and men (aHR, 0.69; P<0.001).
Conclusions-—Compared with men, women lived longer and were less likely to be hospitalized for heart failure after CRT. In both
sexes, CRT-deﬁbrillation was superior to CRT-pacing with respect to survival and heart failure hospitalization. The longest survival
after CRT was observed in women without a history of myocardial infarction. ( J Am Heart Assoc. 2019;8:e013485. DOI: 10.
1161/JAHA.119.013485.)
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C ardiac resynchronization therapy (CRT) is a standardtreatment for selected patients with heart failure (HF),
impaired left ventricular (LV) function and a wide QRS
complex. Sex-speciﬁc differences in the outcome of CRT
was ﬁrst shown by the MIRACLE (Multicenter InSync
Randomized Clinical Evaluation) study,1 in which CRT was
associated with a higher survival free of HF hospitalization in
women than in men, compared with optimum pharmacologic
therapy. A substudy of MADIT-CRT (Multicenter Automatic
Deﬁbrillator Implantation Trial With Cardiac Resynchronization
Therapy) showed that survival and survival free of HF
hospitalization from CRT-deﬁbrillation (CRT-D) compared with
implantable cardioverter-deﬁbrillator (ICD) therapy was higher
in women.2 Data from the US National Cardiovascular Data
Registry also showed that among patients with a left bundle
branch block, the beneﬁt from CRT-D over ICD was greater in
women than in men.3 Better outcomes in women have also
been reported by other observational studies.4–7 and meta-
analyses.8 In contrast, sex-speciﬁc differences in survival
were not observed in COMPANION (Comparison of Medical
Therapy, Pacing and Deﬁbrillation in Heart Failure)9 or CARE-
HF (Cardiac Resynchronization Heart Failure).10
Randomized controlled trials are the cornerstone of evi-
dence-based medicine. However, randomized controlled trials
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tend to comprise a small number of highly selected patients and
a relatively short follow-up. On the other hand, studies using
large administrative data sets have the advantage of large
numbers and a long follow-up but typically lack granularity. In
this context, there is a clear compromise between “wealth of
numbers” and “wealth of detail.” Notwithstanding these
constraints, it is useful to conﬁrm whether the ﬁndings of
randomized controlled trials are also observed in large data sets
that reﬂect real-world clinical practice.
In this study, we explore sex-speciﬁc differences in the
outcomes of CRT in a large, real-world population of CRT
recipients over a long follow-up period. In addition, we
address the relative beneﬁts of CRT-D versus CRT-pacing
(CRT-P) in women and men, with or without a history of
myocardial infarction (MI).
Methods
Data Sources
This is a nonrandomized, retrospective study exploring total
mortality and HF hospitalization after a ﬁrst CRT device
implantation. We have used the National Health Service
Hospital Episode Statistics, a data warehouse containing data
on all admissions to all public hospitals in England. Mortality
data were linked with the Ofﬁce of National Statistics. These
data are available to the University Hospital Birmingham
under a data-sharing agreement (section 251 of the National
Health Service Act 2006), which obviates the need for ethics
committee approval and patient consent. The data presented
herein will not be made available to other researchers, as it is
only provided to researchers with the conditions of this data
sharing agreement. The study was approved by the Clinical
Audit Department at the Queen Elizabeth Hospital, which also
waives patient consent. The study conforms to the Declara-
tion of Helsinki.
Our sample included patients who had their ﬁrst CRT device
implantation between April 1, 2009, and December 1, 2016, in
England. This period was chosen because of the introduction of
reliable coding of CRT-D and CRT-P through the National Tariff.
Second (“redo”) operations were excluded. The underlying
etiology of cardiomyopathy or device indication (primary or
secondary prevention) was not considered. Patients who had
received an ICD without CRT were excluded. This study was
undertaken in the context of the United Kingdom’s National
Institute of Clinical Excellence (NICE) guidelines, which before
2007 recommended CRT-D only in the setting of secondary
prevention. After 2007, the National Institute of Clinical
Excellence recommended CRT-P rather than CRT-D for patients
with nonischemic cardiomyopathy.11 In 2014, the National
Institute of Clinical Excellence recommended CRT-D for
patients with nonischemic cardiomyopathy.11 Consequently,
up to 2014, a large proportion of patients with nonischemic
cardiomyopathy received CRT-P rather than CRT-D.
End Points
The primary end point was total mortality. The secondary end
point was total mortality or HF hospitalization, deﬁned as the
dominant diagnosis in the International Classiﬁcation of
Diseases, Tenth Revision (ICD-10) code I50, that is, the
primary diagnosis of the ﬁrst episode of HF in the hospital
stay. Only data relating to the ﬁrst event (death or HF
hospitalization) were used in these analyses. Table S1 lists the
codes used according to ICD-10 and the Ofﬁce of Population
Censuses and Surveys Classiﬁcation of Interventions and
Procedures-4. Indicator speciﬁcation and hospital-level mor-
tality indicators (Health and Social Care Information Centre)12
were used to minimize missing information.
Comorbidities
The Hospital Episode Statistics for England extends from 2002
to the present. Patients were regarded as having hypertension,
diabetes mellitus, chronic kidney disease, and/or MI if these
diagnoses appeared as primary or secondary diagnoses in any
hospital stay before or at the time of device implantation.
Statistical Analysis
Continuous variables are expressed as mean (SD) and
compared using the Student t test. Categorical variables
were compared using the chi-squared statistic. Kaplan–Meier
curves and the log-rank test were used to assess observed
cumulative survival. Cox proportional hazard models were
Clinical Perspective
What Is New?
• In this study of over 43 000 patients, women survived
longer and were less likely to be hospitalized for heart
failure after cardiac resynchronization therapy (CRT).
• In both women and men, survival and heart failure
hospitalization were lower after CRT-deﬁbrillation than after
CRT-pacing, in both women and men.
• The lowest mortality after CRT was observed in women
without a history of myocardial infarction.
What Are the Clinical Implications?
• The longer survival after CRT in women should be consid-
ered at the time of deciding on device therapy for women, in
whom the uptake of device therapy is disproportionately low
worldwide.
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used to compare risks of total mortality and total mortality
or HF hospitalization. Proportionality hypotheses were ﬁrst
veriﬁed by visual examination of log (survival) graphs to
ensure parallel slopes, and then formally on the basis of
Schoenfeld residuals after ﬁtting Cox models. As the
assumption of proportionality failed for age and device type,
we ﬁtted further Cox models to take into account these
time-varying effects (ie, nonproportional effects). The pres-
ence of multiple interactions between explanatory variables
with sex led to additional parallel analyses by sex. Statistical
analyses were undertaken using Stata 14 (StataCorp,
College Station, TX). A 2-sided P≤0.05 was considered
statistically signiﬁcant.
Results
Baseline Characteristics
Over the study period of 7.6 years, 43 730 patients under-
went CRT implantation (women, 10 890 [24.9%]; men,
32 840 [75.1%]). More men (18 357 [55.9%]) than women
(4283 [39.3%]) underwent CRT-D rather than CRT-P (Table).
Because of the high numbers involved, statistically signiﬁcant
differences (P<0.001) were observed with respect to all
baseline characteristics, despite being numerically small.
Women were younger (by 0.4 years) and were less likely to
have hypertension (64.4% versus 67.8%), diabetes mellitus
(24% versus 29%), chronic kidney disease (12.8% versus
15.1%), or MI (14% versus 22.3%).
Total Mortality
Over a median follow-up of 2.2 years (interquartile range, 1–4
years), a total of 11 030 patients (25.2%) died, corresponding
to 2210 (20.3%) for women and 8820 (26.9%) for men. As
shown in Figure 1, women had a lower total mortality than
men (P<0.001). When stratiﬁed according to device type,
CRT-D in women was associated with the lowest absolute
mortality (Figure 2). In multivariable analyses of the total
population, total mortality (adjusted hazard ratio [aHR], 0.73;
95% CI, 0.70–0.76) after CRT was lower in women, indepen-
dent of age; device type (CRT-P or CRT-D); or history of
hypertension, diabetes mellitus, chronic kidney disease, or MI
(Figure 3A). Similar ﬁndings emerged in within-sex analyses.
HF Hospitalization
In Kaplan–Meier survival analyses (Figure 1), women had a
lower total mortality or HF hospitalization (P<0.001). When
stratiﬁed according to device type, CRT-D in women was
associated with the lowest absolute total mortality or HF
hospitalization (Figure 2). In multivariable analyses of the
total population, total mortality or HF hospitalization was
lower in women (aHR, 0.79; 95% CI, 0.75–0.82), indepen-
dent of known confounders (Figure 3B). In within-sex
analyses, CRT-D was superior to CRT-P with respect to total
mortality or HF hospitalization in men (aHR, 0.76; 95% CI,
0.72–0.81), but not in women (aHR, 0.90; 95% CI, 0.80–
1.01) (Figure 3B).
CRT-D Versus CRT-P
In the total population, CRT-D was associated with a lower total
mortality (aHR, 0.70; 95% CI, 0.66–0.75) and total mortality or
HF hospitalization (aHR, 0.78; 95% CI, 0.74–0.82) (Figures 2
and 3). In separate analyses of women andmen, CRT-Dwas also
associatedwith a lowermortality.With respect to totalmortality
or HF hospitalization, CRT-D was associated with a lower risk in
men (aHR, 0.76; 95% CI, 0.72–0.81) but not in women (aHR,
0.90; 95% CI, 0.80–1.01) (Figures 2 and 3).
Inﬂuence of MI
In Kaplan–Meier survival analyses of patients with a history of
MI, no differences in total mortality or total mortality or HF
hospitalizations emerged between women and men (Fig-
ure 4). In multivariable analyses of patients with a history of
MI, total mortality (aHR, 0.89; 95% CI, 0.80–0.98) and total
mortality or HF hospitalization (aHR, 0.89; 95% CI, 0.82–0.98)
after CRT were lower in women (Figure 5A). In patients
without a history of MI, total mortality (aHR, 0.70; 95% CI,
Table. Characteristics of the Study Group
Men Women
N 32 840 (75.1) 10 890 (24.9)
Age, y 71.211 70.812.5
<60 4659 (14.19) 1747 (16.04)
60–69 7757 (23.62) 2344 (21.52)
70–79 12 687 (38.63) 4145 (38.06)
≥80 7737 (23.56) 2654 (24.37)
Hypertension 22 275 (67.83) 7013 (64.4)
Diabetes mellitus 9525 (29.0) 2616 (24.02)
Chronic kidney disease 4948 (15.07) 1394 (12.8)
MI 7328 (22.31) 1524 (13.99)
Device type
CRT-D 18 357 (55.9) 4283 (39.33)
CRT-P 14 483 (44.1) 6607 (60.67)
Variables are expressed as n (%). All comparisons between women and men were
signiﬁcant (P<0.001). CRT-D indicates cardiac resynchronization therapy–deﬁbrillation;
CRT-P, cardiac resynchronization therapy–pacing; MI, myocardial infarction.
DOI: 10.1161/JAHA.119.013485 Journal of the American Heart Association 3
CRT in Women Leyva et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on November 15, 2019
0.66–0.73) and total mortality or HF hospitalization (aHR,
0.76; 95% CI, 0.73–0.80) after CRT were also lower in women
(Figures 5B).
Discussion
Several ﬁndings have emerged from this study of a large, real-
world population of patients undergoing CRT. First, women
lived longer and were less likely to be hospitalized for HF after
CRT. Second, total mortality and total mortality or HF
hospitalization were lower after CRT-D than after CRT-P in
both women and men. Third, survival after CRT in women was
longest in those without a history of MI.
Total Mortality and HF Hospitalization
We have found that CRT was associated with a better
survival and survival free of HF hospitalization in women.
These ﬁndings are in keeping with a substudy of MADIT-CRT
(Multicenter Automatic Deﬁbrillator Implantation Trial With
Cardiac Resynchronization Therapy), the magnitude of the
beneﬁt from CRT-D versus ICD in terms of survival or
survival free of HF hospitalization was better in women (25%
of the study population) than in men.2 They are also
consistent with the ﬁndings from MIRACLE,1 in which
women had a better survival free of HF hospitalization than
men, compared with optimum pharmacologic therapy.
Moreover, they are in line with registry data from the US
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Figure 1. Clinical outcomes after cardiac resynchronization therapy according to sex.
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Figure 2. Clinical outcomes after cardiac resynchronization therapy according to sex and device type. Kaplan–Meier survival curves for study
end points according to sex and device type. CRT-D indicates cardiac resynchronization therapy–deﬁbrillation; CRT-P, cardiac resynchronization
therapy–pacing; HF, heart failure.
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National Cardiovascular Data Registry, in which beneﬁt from
CRT-D over ICD was greater in women than in men with a
left bundle branch block.3 In a metanalysis of 33 434
patients from 72 studies, women had an ~33% reduction in
total mortality and 20% reduction in total mortality or HF
hospitalization after CRT.8 This is comparable with the
aHR (95% CI) p
0.73 (0.70-0.76) <0.001
1.03 (1.03-1.04) <0.001
1.10 (1.05-1.15) <0.001
1.31 (1.26-1.37) <0.001
1.99 (1.89-2.08) <0.001
1.25 (1.20-1.31) <0.001
0.70 (0.66-0.75) <0.001
1.09 (1.07-1.12) <0.001
1.00 (1.00-1.00) <0.001
0.5 1.0 1.5 2.0 2.5 
aHR
Sex (female) 
Age (per year) 
Hypertension 
Diabetes mellitus 
Chronic kidney disease 
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Device type (CRT-D)
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Figure 3. Multivariable analyses. Analyses refer to (A) total mortality and (B) total mortality or heart
failure (HF) hospitalization. Results are shown in terms of adjusted hazard ratios (aHR) and 95% CI. CRT-D
indicates cardiac resynchronization therapy–deﬁbrillation.
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reductions observed after CRT in women versus men in the
present study (27% and 21%, respectively).
The reasons for better outcomes after CRT in women are
unclear. We have observed, however, that women were less
likely to have had an MI (14% versus 22%, respectively) and that
the survival advantage of women overmen after CRTwas higher
in thosewithout a history ofMI. This suggests that at least some
of the survival beneﬁt from CRT in women over men relates to
ALL PATIENTS 
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FEMALE 
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Figure 3. Continued
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the etiology of the underlying cardiomyopathy. In this respect,
several studies have shown that CRT inwomen is better in those
with nonischemic cardiomyopathy.7,13,14 In multivariable anal-
yses comprising MI as a covariable, the HR for CRT-D versus
CRT-P was lower in men (0.69; P<0.001) than in women (0.83;
P=0.013), suggesting a lower efﬁcacy of CRT-D in women.
Another explanation for a sex-speciﬁc difference in CRT
responsemay relate toQRS duration, which is shorter in healthy
women and in women undergoing CRT.15 Accordingly, conduc-
tion disturbances and LV dyssynchrony may be more prevalent
in women at a given QRS duration, perhaps accounting for their
superior beneﬁt from CRT. Another contributing factor may be
the correlation between QRS duration and cardiac as well as
body size.16 In this respect, it is possible that men have a longer
QRS duration simply because of LV mass and body size, rather
than LV dyssynchrony.17
The possible effects of estrogen and testosterone on CRT
response has not been explored. It is noteworthy that in the
Danish Osteoporosis Prevention Study, hormone replacement
therapy in women was associated with a reduced lower risk of
the composite end point of mortality, HF, and MI.18 On the
other hand, hormone replacement therapy is associated with
lower LV end-diastolic volumes and left atrial volumes,19 both
of which have been associated with better clinical outcomes
in patients with HF. These ﬁndings raise the possibility that
menopausal status may inﬂuence the CRT response. Unfor-
tunately, our data set does not include menopausal status.
CRT-D Versus CRT-P
Individual studies and metanalyses8 on sex-speciﬁc differences
in outcomes after CRT have used different comparators, and it is
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Figure 4. Clinical outcomes after cardiac resynchronization therapy according to sex and history of MI. Kaplan–Meier survival curves
according to sex and history of MI. HF indicates heart failure; MI, myocardial infarction.
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therefore difﬁcult to determine whether the more favorable
effects of CRT in women are due to resynchronization or
deﬁbrillation. In this respect, theMADIT-CRT subanalysis, which
compared CRT-D with ICD, found more favorable outcomes in
women,2 suggesting that the survival beneﬁt from CRT-D over
ICD in women was due to resynchronization per se. Arguably,
the answer to this question lies in comparisons of CRT-D versus
CRT-P. In a recent retrospective study of propensity-matched
(inverse-probability weighting) cohorts of 209 CRT-D recipients
and 209 CRT-P recipients CRT-D was not associated with a
survival beneﬁt over CRT-P in women (HR, 0.87; 95% CI, 0.63–
1.19).20 In the present study, however, we found that survival
was better in both women andmen after both CRT-D and CRT-P.
In separate analyses, the difference in survival between CRT-D
and CRT-P was more pronounced in men (31%) than in women
(17%), suggesting that deﬁbrillation is more effective in men.
Uptake of CRT in Women
We found a lower proportion of women than men undergoing
CRT, amounting to 25% of the study population. These
ﬁndings are in keeping with the 2008 European CRT survey in
which 27% of CRT recipients were women.21 Admittedly, the
lower proportion of CRT female recipients could simply be due
to a lower prevalence of HF in women, rather than a lower
utilization in potential CRT candidates. In this respect, a
national audit of 55 959 patients over 45 years with a new
diagnosis of HF in the period 2000 to 2017 in England, the
proportion of women and men were 47.8% and 52.2%,
respectively.22 The disparity between the relative incidence of
HF in women (47.8%) and the proportion of women receiving
CRT in the present study (25%) raises the possibility of a bias
toward underutilization of CRT in women. Further studies on
CRT implantation rates in women with indications for CRT are
needed to clarify this issue.
Limitations
This study has the typical limitations of an observational,
retrospective study using data from administrative databases,
which typically lack granularity. First, we do not have data on the
etiology of the underlying cardiomyopathy, LV function, QRS
duration or morphology, or medication, all of which have been
TOTAL MORTALITY OR HF HOSPITALIZATION 
PATIENTS WITH MI 
TOTAL MORTALITY 
0.5 1.0 1.5 2.0 2.5 
Sex (female) 
Age (per year) 
Hypertension 
Diabetes mellitus 
Chronic kidney disease 
Device type (CRT-D)
CRT-D * time interaction 
Age * time interaction 
0.5 1.0 1.5 2.0 2.5
Sex (female) 
Age (per year) 
Hypertension 
Diabetes mellitus 
Chronic kidney disease 
Device type (CRT-D)
CRT-D * time interaction 
Age * time interaction 
0.89 (0.80-0.98) 0.022
1.03 (1.02-1.03) <0.001
1.02 (0.92-1.14) 0.642
1.24 (1.15-1.35) <0.001
1.92 (1.76-2.10) <0.001
0.64 (0.56-0.73) <0.001
1.11 (1.05-1.16) <0.001
1.00 (1.00-1.01) 0.037
0.89 (0.82-0.98) 0.012
1.01 (1.01-1.02) <0.001
1.06 (0.97-1.16) 0.203
1.33 (1.24-1.42) <0.001
1.86 (1.72-2.01) <0.001
0.72 (0.65-0.80) <0.001
1.09 (1.04-1.14) <0.001
1.00 (1.00-1.01) 0.004
aHR (95% CI) p
aHR (95% CI) p
aHR
aHR
A PATIENTS WITHOUT MI 
0.5 1.0 1.5 2.0 2.5 
Sex (female) 
Age (per year) 
Hypertension 
Diabetes mellitus 
Chronic kidney disease 
Device type (CRT-D)
CRT-D * time interaction 
Age * time interaction 
aHR
0.5 1.0 1.5 2.0 2.5 
Sex (female) 
Age (per year) 
Hypertension 
Diabetes mellitus 
Chronic kidney disease 
Device type (CRT-D)
CRT-D * time interaction 
Age * time interaction 
aHR
TOTAL MORTALITY OR HF HOSPITALIZATION 
TOTAL MORTALITY 
0.70 (0.66-0.73) <0.001
1.03 (1.03-1.04) <0.001
1.11 (1.06-1.17) <0.001
1.33 (1.27-1.40) <0.001
2.01 (1.90-2.13) <0.001
0.73 (0.67-0.78) <0.001
1.09 (1.06-1.12) <0.001
1.00 (1.00-1.01) <0.001
0.76 (0.73-0.80) <0.001
1.02 (1.02-1.02) <0.001
1.17 (1.12-1.22) <0.001
1.35 (1.29-1.41) <0.001
1.96 (1.86-2.06) <0.001
0.80 (0.76-0.85) <0.001
1.08 (1.06-1.11) <0.001
1.00 (1.00-1.01) <0.001
aHR (95% CI) p
aHR (95% CI) p
B 
Figure 5. Multivariable analyses: inﬂuence of myocardial infarction (MI). Analyses refer to patients with (A) or without (B) a history of MI. Results
are shown in terms of adjusted hazard ratio (aHR) and 95% CI. CRT-D indicates cardiac resynchronization therapy–deﬁbrillation; HF, heart failure.
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linked to the response to CRT in women.2 Second, comorbidities
tend to be underreported in our administrative database,23
although we have no reason to believe that this underreporting
was different in women versus men. Third, we have not included
optimum pharmacologic therapy group, and therefore we cannot
comment on the relative beneﬁts of CRT versus optimum
pharmacologic therapy. Fourth, to explore the relative beneﬁts of
CRT-D over CRT-P, we used history of MI as a surrogate. This,
however, does not equate to an underlying ischemic etiology of
heart failure. Finally, as for the ﬁndings of fewer HF hospitaliza-
tions after CRT-D than after CRT-P in men, we should consider
that hospitalizations coded as an HF hospitalization may have
been provoked or associated with treated ventricular arrhyth-
mias. Unfortunately, we have no data on concurrent ventricular
arrhythmias or ICD therapies delivered.
Conclusions
We have found that in a large, real-world population of
patients undergoing CRT, women survived longer and were
less likely to be hospitalized for HF after CRT. In both women
and men, CRT-D was superior to CRT-P with respect to
survival and survival free of HF hospitalization. The lowest
survival after CRT was observed in women without a history of
MI. These factors should be considered at the time of deciding
on device therapy for women, in whom the uptake of device
therapy is disproportionately low worldwide.
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Table S1. Diagnostic and procedural codes 
 
 
 
 
 
 
 
 
Corresponding diagnostic codes were obtained from the International Classification 
of Diseases 10th revision (ICD-10), and the Office of Population Censuses and 
Surveys Classification of Interventions and Procedures version 4 (OPCS-4) for 
procedural codes. 
 
 
 OPCS-4  
CRT-D K596 
CRT-P K6[0.1]7 
 ICD10 
Hypertension I10 
Diabetes mellitus E1[0.1.3.4][1.5.6.8.9] 
Chronic kidney disease N18 
Heart failure I50 
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